| Title: |
Efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson’s disease: a systematic review and meta-analysis of randomized placebo-controlled clinical trials |
| Authors: |
Stefanou, Maria-Ioanna; Panagiotopoulos, Evangelos; Tentolouris, Anastasios; Theodorou, Aikaterini; Papagiannopoulou, Georgia; Athanasaki, Athanasia; Tsalouchidou, Panagiota-Eleni; Peppa, Melpomeni; Lambadiari, Vaia; Konitsiotis, Spiridon; Mengel, Annerose; Paraskevas, Georgios P.; Tentolouris, Nikolaos; Tsivgoulis, Georgios |
| Source: |
Therapeutic Advances in Neurological Disorders ; volume 19 ; ISSN 1756-2864 1756-2864 |
| Publisher Information: |
SAGE Publications |
| Publication Year: |
2026 |
| Description: |
Background: Converging lines of preclinical evidence support the neuroprotective properties of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Parkinson’s disease (PD). Nevertheless, results from randomized-controlled clinical trials (RCTs) remain conflicting. Objectives: To assess the safety and efficacy of GLP-1 RAs in PD. Design: Systematic review and meta-analysis of randomized placebo-controlled clinical trials. Data sources and methods: A systematic search of MEDLINE and Scopus databases was conducted on October 7, 2025, for randomized placebo-controlled clinical trials investigating GLP-1 RAs in adults with PD. Risk of bias was evaluated using the Cochrane Collaboration risk-of-bias (RoB2) tool. Results: Four RCTs comprising 667 PD patients (377 receiving GLP-1 RAs) were included. Between baseline and end-of-treatment, no differences were observed in the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part III score change between GLP-1 RA- and placebo-treated patients in either off-medication (standardized mean difference (SMD): −0.16; 95% CI: −0.64 to 0.32; p = 0.52) or on-medication states (SMD: −0.13; 95% confidence interval (CI): −0.51 to 0.25; p = 0.49). No significant differences were uncovered in other MDS-UPDRS subscores, Non-Motor Symptoms Scale, Montreal Cognitive Assessment, or Parkinson’s Disease Questionnaire scores. The risk of serious adverse events and odds of treatment discontinuation were similar between groups, but GLP-1 RAs were associated with an increased risk of weight loss compared to placebo (risk ratio: 1.44; 95% CI: 1.04–1.99; p = 0.03). Conclusion: GLP-1 RAs were not associated with improvements in motor or non-motor domains of PD. However, robust preclinical evidence and promising findings in select subpopulations warrant further RCTs to evaluate their neuroprotective potential, prioritizing long-acting and brain-penetrant agents that effectively engage central GLP-1 circuits for PD treatment. Registration: The pre-specified protocol of ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1177/17562864251408269 |
| Availability: |
https://doi.org/10.1177/17562864251408269; https://journals.sagepub.com/doi/pdf/10.1177/17562864251408269; https://journals.sagepub.com/doi/full-xml/10.1177/17562864251408269 |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ ; https://journals.sagepub.com/page/policies/text-and-data-mining-license |
| Accession Number: |
edsbas.F5209C1D |
| Database: |
BASE |